Bayer Aktiengesellschaft

The Broad Institute, Inc.

Dana-farber-cancer Institute Inc.

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Daniel Korr

Ulf Bömer

Knut Eis

Philip Lienau

Ludwig Zorn

Matthew Meyerson

Arne Scholz

Mark Jean Gnoth

Judith Günther

Stephan Siegel

Heidi Greulich

Florian Pühler

Jörg Fanghänel

Bethany Kaplan

Ulrich Klar

Markus Berger

Roland Neuhaus

Detlev Sülzle

Volker Schulze

Ursula Mönning

Steven James Ferrara

Kirstin Petersen

Keith Graham

Stefan Nikolaus Gradl

Antonius Ter Laak

Jens Schröder

Simon Anthony Herbert

Dieter Moosmayer

Michael Niehues

Franziska Siegel

Uwe Eberspächer

Roman Hillig

Naomi Barak

Vera Pütter

Matyas Gorjanacz

Stefan Niklaus Gradl

Hassan Youssef Harb

Craig Strathdee

Jacob Jaffe

Ernesto Amaury Fernandez-Montalvan

Léa Aurelie Bouché

Phi Manh Dinh

Amaury Ernesto Fernandez-montalvan

Jacob D Jaffe

Eis Knut

Ulf BÖMER

Jörg FANGHÄNEL

Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present invention provides acyl sulfonamide compounds of general formula (I):

Acyl sulfonamides for treating cancer

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Substituted aminoimidazopyridazines

The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Heterocyclyl aminoimidazopyridazines

Growing community of inventors

Berlin, Germany

Daniel Korr